Loading Bonafide Research

Asia Pacific In Vitro Diagnostics (IVD) Market Outlook, 2030

The Asia-Pacific in vitro diagnostics (IVD) market will grow by 7%, driven by healthcare expansion and innovation.

The Asia Pacific In Vitro Diagnostics (IVD) market is experiencing explosive growth, driven by a complex interplay of socioeconomic factors, evolving healthcare infrastructure, and increasing awareness of preventive care. The rapid expansion of the middle class across countries like China, India, and Southeast Asian nations is significantly boosting healthcare expenditure, leading to greater access to and demand for advanced diagnostic services. The region’s burgeoning population, coupled with an aging demographic, is contributing to a rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer, necessitating early and accurate diagnosis. The increasing adoption of personalized medicine, driven by advancements in genomics and proteomics, is fueling the demand for sophisticated IVD technologies. The growing awareness of infectious diseases, particularly with the emergence of new viral strains, is driving the need for robust diagnostic solutions. The COVID-19 pandemic served as a pivotal catalyst, highlighting the critical role of IVD in pandemic management and accelerating the adoption of molecular diagnostics, especially PCR-based testing. The expansion of healthcare infrastructure, including the establishment of new hospitals and diagnostic laboratories, is improving access to IVD services in both urban and rural areas. The increasing focus on preventive healthcare and early disease detection is driving the demand for routine check-ups and screening programs. The rising adoption of point-of-care testing (POCT) is improving accessibility and reducing turnaround times, particularly in remote and underserved regions. The growing emphasis on quality control and standardization in laboratory testing is driving the demand for high-quality IVD products. The increasing availability of reimbursement for advanced IVD tests is supporting market growth. The increasing adoption of automation and digitalization in laboratory settings is improving efficiency and reducing turnaround times. The growing demand for companion diagnostics, which are used to identify patients who are likely to benefit from specific therapies, is also contributing to market expansion.

The Asia Pacific in vitro diagnostics (IVD) market will grow by 7.8% annually with a total addressable market cap of $303,673.6 million over the period from 2022 to 2031. The growth is driven by factors such as the increasing prevalence of chronic diseases, the growing geriatric population, the demand for automation in diagnostics, the development of condition-specific treatments, awareness of personalized medicines, the emergence of minimally invasive and non-invasive diagnostic tools and techniques, rising healthcare expenditure, and increased demand for point-of-care (POC) testing. The Asia Pacific In Vitro Diagnostics (IVD) market is witnessing a "democratization" trend, characterized by the increasing accessibility and affordability of diagnostic services across diverse socioeconomic strata. This "democratization" is driven by several key "drivers," including the expanding middle class, the rising prevalence of chronic diseases, and the growing demand for preventive healthcare. The "drivers" are further amplified by the increasing awareness of infectious diseases and the need for rapid and accurate diagnostics. The "democratization" is also driven by the expansion of healthcare infrastructure and the increasing adoption of point-of-care testing. The "drivers" are further intensified by the COVID-19 pandemic, which highlighted the critical role of accessible diagnostics. The "democratization" is also being fueled by the increasing availability of reimbursement and the growing emphasis on quality control. The "drivers" are supported by various "programs," including government initiatives aimed at improving healthcare access and affordability, as well as industry-led efforts to develop cost-effective diagnostic solutions. These "programs" are designed to facilitate the "democratization" of the IVD market by providing funding, regulatory guidance, and technical assistance. The "drivers" are also influenced by the increasing adoption of automation and digitalization in laboratories. The "programs" are also aimed at enhancing the quality and accuracy of laboratory testing. The "democratization" is further supported by the growing demand for self-testing and home-based diagnostics. The "drivers" are also being shaped by the increasing adoption of next-generation sequencing and companion diagnostics. The "programs" are also designed to promote the development of rapid and accurate infectious disease diagnostics. The "democratization" is also being driven by the need for accessible diagnostics in rural and underserved regions. The "drivers" are also influenced by the increasing focus on preventive care and early disease detection. The "programs" are also aimed at supporting the integration of advanced technologies in IVD. The "democratization" is ultimately aimed at improving healthcare outcomes and reducing disparities in access to diagnostic services.
The Asia Pacific In Vitro Diagnostics (IVD) market is segmented by product, encompassing a wide array of diagnostic tools and consumables. "Reagents and Kits" form a substantial segment, providing essential components for immunoassays, molecular diagnostics, and clinical chemistry. "Instruments" include analyzers, sequencers, and imaging systems used for sample processing and analysis. "Software and Services" encompass laboratory information systems (LIS) and data management solutions. "Consumables" like sample collection tubes and pipette tips are critical for testing. "Immunoassay Kits" detect analytes via antigen-antibody reactions. "Molecular Diagnostic Kits" utilize PCR and NGS for genetic and pathogen detection. "Clinical Chemistry Reagents" measure biochemical markers. "Microbiology Kits" identify pathogens. "Hematology Reagents" analyze blood cells. "Coagulation Reagents" assess blood clotting. "Point-of-Care Testing (POCT) Devices" enable rapid testing. "Liquid Biopsy Kits" detect circulating tumor DNA. These segments meet the diverse diagnostic needs of the region's healthcare systems.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


The Asia Pacific In Vitro Diagnostics (IVD) market is segmented by technology, reflecting the diverse analytical techniques used. "Immunoassays" utilize antigen-antibody interactions. "Molecular Diagnostics" employ PCR and NGS. "Clinical Chemistry" measures biochemical markers. "Microbiology" identifies pathogens. "Hematology" analyzes blood cells. "Coagulation" assesses blood clotting. "Point-of-Care Testing (POCT)" provides rapid testing. "Liquid Biopsy" detects circulating tumor DNA. "Next-Generation Sequencing (NGS)" provides comprehensive genomic data. "Mass Spectrometry" identifies molecules. "Flow Cytometry" analyzes cell characteristics. "In Situ Hybridization" detects specific DNA/RNA sequences. These technologies enable accurate and timely diagnosis.

The Asia Pacific In Vitro Diagnostics (IVD) market is segmented by sample type, reflecting diverse biological specimens. "Blood" is widely used for many tests. "Urine" detects various analytes. "Saliva" is used for non-invasive testing. "Tissue" is used for histopathology. "Cerebrospinal Fluid (CSF)" diagnoses neurological disorders. "Sputum" diagnoses respiratory infections. "Stool" diagnoses gastrointestinal infections. "Buccal Swabs" collect DNA. "Plasma" and "Serum" are blood components. "Other Body Fluids" are used for specific diagnoses. Sample selection depends on the test.

The Asia Pacific In Vitro Diagnostics (IVD) market is segmented by application, reflecting diverse clinical areas. "Infectious Diseases" are a major focus, especially post-COVID-19. "Oncology" detects and monitors cancer. "Cardiology" diagnoses heart diseases. "Immunology" addresses immune disorders. "Nephrology" focuses on kidney diseases. "Diabetes" monitors blood sugar. "Hematology" analyzes blood. "Genetic Testing" diagnoses genetic disorders. "Drug Testing" detects substances. "Point-of-Care Testing (POCT)" provides rapid results. "Women’s Health" addresses specific needs. "Microbiology" identifies pathogens. "Clinical Chemistry" measures biochemical markers. These applications meet the region's diverse healthcare needs.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



The Asia Pacific In Vitro Diagnostics (IVD) market is segmented by end user, reflecting diverse healthcare settings. "Hospitals and Clinics" are major users. "Diagnostic Laboratories" perform high-volume testing. "Point-of-Care Testing (POCT)" occurs in various settings. "Home Care Settings" use self-testing. "Academic and Research Institutes" perform research. "Pharmaceutical and Biotechnology Companies" use tests for drug development. "Blood Banks" screen blood. "Public Health Laboratories" monitor outbreaks. "Forensic Laboratories" use tests for investigations. "Veterinary Laboratories" diagnose animal diseases. These end users drive IVD demand.


The Asia Pacific In Vitro Diagnostics (IVD) market is segmented by country, with key players like China, India, Japan, and Australia. "China" is a dominant market, driven by a large population, growing middle class, and increasing healthcare expenditure. "India" is a rapidly growing market, with increasing healthcare infrastructure and rising awareness of preventive care. "Japan" is a mature market, with a focus on advanced technologies and an aging population. "Australia" is a developed market, with a strong focus on quality and innovation. "Southeast Asian Countries" like Indonesia, Thailand, and Vietnam are emerging markets, with increasing healthcare access and growing demand for IVD services. Each country has unique market dynamics and growth drivers.

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari

Table of Contents

  • 1 Introduction 7
  • 1.1 Industry Definition and Research Scope 7
  • 1.1.1 Industry Definition 7
  • 1.1.2 Research Scope 8
  • 1.2 Research Methodology 11
  • 1.2.1 Overview of Market Research Methodology 11
  • 1.2.2 Market Assumption 12
  • 1.2.3 Secondary Data 12
  • 1.2.4 Primary Data 12
  • 1.2.5 Data Filtration and Model Design 13
  • 1.2.6 Market Size/Share Estimation 14
  • 1.2.7 Research Limitations 15
  • 1.3 Executive Summary 16
  • 2 Market Overview and Dynamics 19
  • 2.1 Market Size and Forecast 19
  • 2.1.1 Impact of COVID-19 on World Economy 20
  • 2.1.2 Impact of COVID-19 on the Market 24
  • 2.2 Major Growth Drivers 26
  • 2.3 Market Restraints and Challenges 32
  • 2.4 Emerging Opportunities and Market Trends 35
  • 2.5 Porter’s Fiver Forces Analysis 39
  • 3 Segmentation of Asia Pacific Market by Product 43
  • 3.1 Market Overview by Product 43
  • 3.2 Instruments & Devices 45
  • 3.2.1 Disposable IVD Devices 46
  • 3.2.2 Reusable IVD Devices 47
  • 3.3 Reagents & Kits 48
  • 3.4 Software & Services 49
  • 4 Segmentation of Asia Pacific Market by Technology 50
  • 4.1 Market Overview by Technology 50
  • 4.2 Clinical Chemistry 52
  • 4.3 Molecular Diagnostics 53
  • 4.4 Immuno Diagnostics 54
  • 4.5 Hematology 55
  • 4.6 Tissue Diagnostics 56
  • 4.7 Microbiology 57
  • 4.8 Coagulation and Hemostasis 58
  • 4.9 Urinalysis 59
  • 4.10 Other Technologies 60
  • 5 Segmentation of Asia Pacific Market by Sample Type 61
  • 5.1 Market Overview by Sample Type 61
  • 5.2 Blood 63
  • 5.3 Mucus 64
  • 5.4 Urine 65
  • 5.5 Other Sample Types 66
  • 6 Segmentation of Asia Pacific Market by Application 67
  • 6.1 Market Overview by Application 67
  • 6.2 Infectious Diseases 69
  • 6.3 Diabetes 79
  • 6.4 Cancer/Oncology 80
  • 6.5 Cardiology 81
  • 6.6 Autoimmune Disease 82
  • 6.7 Nephrology 83
  • 6.8 Drug Testing 84
  • 6.9 HIV/AIDS 85
  • 6.10 Other Applications 86
  • 7 Segmentation of Asia Pacific Market by End User 87
  • 7.1 Market Overview by End User 87
  • 7.2 Diagnostic Laboratories 89
  • 7.3 Hospitals and Clinics 90
  • 7.4 Homecare Settings 91
  • 7.5 Point-of-Care (POC) Settings 92
  • 7.6 Other End Users 93
  • 8 Asia-Pacific Market 2021-2031 by Country 94
  • 8.1 Overview of Asia-Pacific Market 94
  • 8.2 Japan 97
  • 8.3 China 100
  • 8.4 Australia 102
  • 8.5 India 104
  • 8.6 South Korea 106
  • 8.7 Rest of APAC Region 108
  • 9 Competitive Landscape 110
  • 9.1 Overview of Key Vendors 110
  • 9.2 New Product Launch, Partnership, Investment, and M&A 113
  • 9.3 Company Profiles 114
  • Abbott Laboratories, Inc. 114
  • Agilent Technologies, Inc. 116
  • Arkray Inc. 117
  • Becton, Dickinson and Company 118
  • Biomerieux SA 119
  • Bio-Rad Laboratories Inc. 120
  • Danaher Corporation 121
  • DiaSorin SpA (Luminex Corporation) 122
  • Epic Systems Corporation 123
  • F. Hoffmann-La Roche Ltd. 124
  • Genpact Limited 125
  • Grifols SA 126
  • IBM Corporation 127
  • Mckesson Corporation 128
  • Ortho Clinical Diagnostics Inc. 129
  • Qiagen NV 130
  • Quest Diagnostics Inc. 131
  • Quidel Corporation 132
  • Roche Diagnostics 133
  • Siemens Healthineers 134
  • Sysmex Corporation 135
  • Thermo Fisher Scientific Inc. 136
  • RELATED REPORTS 137

List of Figures:

Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. Asia Pacific In Vitro Diagnostics Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 24
Figure 6. Primary Drivers and Impact Factors of Asia Pacific In Vitro Diagnostics Market 26
Figure 7. Leading Causes of Death in the World, 2000 and 2019, million 29
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 30
Figure 10. Primary Restraints and Impact Factors of Asia Pacific In Vitro Diagnostics Market 32
Figure 11. Investment Opportunity Analysis 36
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific In Vitro Diagnostics Market 39
Figure 13. Breakdown of Asia Pacific In Vitro Diagnostics Market by Product, 2021-2031, % of Revenue 44
Figure 14. Asia Pacific Addressable Market Cap in 2022-2031 by Product, Value ($ mn) and Share (%) 44
Figure 15. Asia Pacific In Vitro Diagnostics Market by Product: Instruments & Devices, 2021-2031, $ mn 45
Figure 16. Asia Pacific In Vitro Diagnostics Market by Instruments & Devices: Disposable IVD Devices, 2021-2031, $ mn 46
Figure 17. Asia Pacific In Vitro Diagnostics Market by Instruments & Devices: Reusable IVD Devices, 2021-2031, $ mn 47
Figure 18. Asia Pacific In Vitro Diagnostics Market by Product: Reagents & Kits, 2021-2031, $ mn 48
Figure 19. Asia Pacific In Vitro Diagnostics Market by Product: Software & Services, 2021-2031, $ mn 49
Figure 20. Breakdown of Asia Pacific In Vitro Diagnostics Market by Technology, 2021-2031, % of Sales Revenue 51
Figure 21. Asia Pacific Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%) 51
Figure 22. Asia Pacific In Vitro Diagnostics Market by Technology: Clinical Chemistry, 2021-2031, $ mn 52
Figure 23. Asia Pacific In Vitro Diagnostics Market by Technology: Molecular Diagnostics, 2021-2031, $ mn 53
Figure 24. Asia Pacific In Vitro Diagnostics Market by Technology: Immuno Diagnostics, 2021-2031, $ mn 54
Figure 25. Asia Pacific In Vitro Diagnostics Market by Technology: Hematology, 2021-2031, $ mn 55
Figure 26. Asia Pacific In Vitro Diagnostics Market by Technology: Tissue Diagnostics, 2021-2031, $ mn 56
Figure 27. Asia Pacific In Vitro Diagnostics Market by Technology: Microbiology, 2021-2031, $ mn 57
Figure 28. Asia Pacific In Vitro Diagnostics Market by Technology: Coagulation and Hemostasis, 2021-2031, $ mn 58
Figure 29. Asia Pacific In Vitro Diagnostics Market by Technology: Urinalysis, 2021-2031, $ mn 59
Figure 30. Asia Pacific In Vitro Diagnostics Market by Technology: Other Technologies, 2021-2031, $ mn 60
Figure 31. Breakdown of Asia Pacific In Vitro Diagnostics Market by Sample Type, 2021-2031, % of Sales Revenue 62
Figure 32. Asia Pacific Addressable Market Cap in 2022-2031 by Sample Type, Value ($ mn) and Share (%) 62
Figure 33. Asia Pacific In Vitro Diagnostics Market by Sample Type: Blood, 2021-2031, $ mn 63
Figure 34. Asia Pacific In Vitro Diagnostics Market by Sample Type: Mucus, 2021-2031, $ mn 64
Figure 35. Asia Pacific In Vitro Diagnostics Market by Sample Type: Urine, 2021-2031, $ mn 65
Figure 36. Asia Pacific In Vitro Diagnostics Market by Sample Type: Other Sample Types, 2021-2031, $ mn 66
Figure 37. Breakdown of Asia Pacific In Vitro Diagnostics Market by Application, 2021-2031, % of Revenue 68
Figure 38. Asia Pacific Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 68
Figure 39. Asia Pacific In Vitro Diagnostics Market by Application: Infectious Diseases, 2021-2031, $ mn 69
Figure 40. Asia Pacific In Vitro Diagnostics Market by Application: Diabetes, 2021-2031, $ mn 79
Figure 41. Asia Pacific In Vitro Diagnostics Market by Application: Cancer/Oncology, 2021-2031, $ mn 80
Figure 42. Asia Pacific In Vitro Diagnostics Market by Application: Cardiology, 2021-2031, $ mn 81
Figure 43. Asia Pacific In Vitro Diagnostics Market by Application: Autoimmune Disease, 2021-2031, $ mn 82
Figure 44. Asia Pacific In Vitro Diagnostics Market by Application: Nephrology, 2021-2031, $ mn 83
Figure 45. Asia Pacific In Vitro Diagnostics Market by Application: Drug Testing, 2021-2031, $ mn 84
Figure 46. Asia Pacific In Vitro Diagnostics Market by Application: HIV/AIDS, 2021-2031, $ mn 85
Figure 47. Asia Pacific In Vitro Diagnostics Market by Application: Other Applications, 2021-2031, $ mn 86
Figure 48. Breakdown of Asia Pacific In Vitro Diagnostics Market by End User, 2021-2031, % of Revenue 88
Figure 49. Asia Pacific Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 88
Figure 50. Asia Pacific In Vitro Diagnostics Market by End User: Diagnostic Laboratories, 2021-2031, $ mn 89
Figure 51. Asia Pacific In Vitro Diagnostics Market by End User: Hospitals and Clinics, 2021-2031, $ mn 90
Figure 52. Asia Pacific In Vitro Diagnostics Market by End User: Homecare Settings, 2021-2031, $ mn 91
Figure 53. Asia Pacific In Vitro Diagnostics Market by End User: Point-of-Care (POC) Settings, 2021-2031, $ mn 92
Figure 54. Asia Pacific In Vitro Diagnostics Market by End User: Other End Users, 2021-2031, $ mn 93
Figure 55. Breakdown of APAC In Vitro Diagnostics Market by Country, 2021 and 2031, % of Revenue 95
Figure 56. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 96
Figure 57. In Vitro Diagnostics Market in Japan, 2021-2031, $ mn 98
Figure 58. In Vitro Diagnostics Market in China, 2021-2031, $ mn 100
Figure 59. In Vitro Diagnostics Market in Australia, 2021-2031, $ mn 102
Figure 60. In Vitro Diagnostics Market in India, 2021-2031, $ mn 104
Figure 61. In Vitro Diagnostics Market in South Korea, 2021-2031, $ mn 106
Figure 62. In Vitro Diagnostics Market in Rest of APAC, 2021-2031, $ mn 108
Figure 63. Growth Stage of Asia Pacific In Vitro Diagnostics Industry over the Forecast Period 110

List of Tables:

Table 1. Snapshot of Asia Pacific In Vitro Diagnostics Market in Balanced Perspective, 2021-2031 17
Table 2. World Economic Outlook, 2021-2031 21
Table 3. World Economic Outlook, 2021-2023 22
Table 4. World Health Spending by Region, $ bn, 2013-2020 31
Table 5. Main Product Trends and Market Opportunities in Asia Pacific In Vitro Diagnostics Market 35
Table 6. Asia Pacific In Vitro Diagnostics Market by Product, 2021-2031, $ mn 43
Table 7. Asia Pacific In Vitro Diagnostics Market: Instruments & Devices by Type, 2021-2031, $ mn 45
Table 8. Asia Pacific In Vitro Diagnostics Market by Technology, 2021-2031, $ mn 50
Table 9. Asia Pacific In Vitro Diagnostics Market by Sample Type, 2021-2031, $ mn 61
Table 10. Asia Pacific In Vitro Diagnostics Market by Application, 2021-2031, $ mn 67
Table 11. Commercially Available COVID-19 Diagnostic Tests Approved in 2021-2022 70
Table 12. Asia Pacific In Vitro Diagnostics Market by End User, 2021-2031, $ mn 87
Table 13. APAC In Vitro Diagnostics Market by Country, 2021-2031, $ mn 95
Table 14. Japan In Vitro Diagnostics Market by Product, 2021-2031, $ mn 99
Table 15. Japan In Vitro Diagnostics Market by Sample Application, 2021-2031, $ mn 99
Table 16. Japan In Vitro Diagnostics Market by End User, 2021-2031, $ mn 99
Table 17. China In Vitro Diagnostics Market by Product, 2021-2031, $ mn 101
Table 18. China In Vitro Diagnostics Market by Sample Application, 2021-2031, $ mn 101
Table 19. China In Vitro Diagnostics Market by End User, 2021-2031, $ mn 101
Table 20. Australia In Vitro Diagnostics Market by Product, 2021-2031, $ mn 103
Table 21. Australia In Vitro Diagnostics Market by Sample Application, 2021-2031, $ mn 103
Table 22. Australia In Vitro Diagnostics Market by End User, 2021-2031, $ mn 103
Table 23. India In Vitro Diagnostics Market by Product, 2021-2031, $ mn 105
Table 24. India In Vitro Diagnostics Market by Sample Application, 2021-2031, $ mn 105
Table 25. India In Vitro Diagnostics Market by End User, 2021-2031, $ mn 105
Table 26. South Korea In Vitro Diagnostics Market by Product, 2021-2031, $ mn 107
Table 27. South Korea In Vitro Diagnostics Market by Sample Application, 2021-2031, $ mn 107
Table 28. South Korea In Vitro Diagnostics Market by End User, 2021-2031, $ mn 107
Table 29. In Vitro Diagnostics Market in Rest of APAC by Country/Region, 2021-2031, $ mn 109
Table 30. Abbott Laboratories, Inc.: Company Snapshot 114
Table 31. Abbott Laboratories, Inc.: Business Segmentation 115
Table 32. Abbott Laboratories, Inc.: Product Portfolio 115
Logo

Asia Pacific In Vitro Diagnostics (IVD) Market Outlook, 2030

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Claude Summarize

Contact usWe are friendly and approachable, give us a call.